Axcelead Drug Discovery Partners specializes in integrated drug discovery and development, focusing on high-value therapeutic candidates across various therapeutic areas, including oncology, immunology, neuroscience, and cardiovascular/metabolic diseases. The company employs a comprehensive end-to-end platform that encompasses several key processes, such as target identification and validation, hit identification and characterization, lead generation and optimization, and candidate selection for IND (Investigational New Drug) applications. Their approach leverages advanced technologies, including high-throughput screening (HTS) with a library of over 1.5 million compounds, and incorporates in-silico systems utilizing artificial intelligence to enhance rational drug design and compound delivery.

In addition to small molecules, Axcelead is actively engaged in the development of innovative therapeutic modalities, such as RNA-targeted small molecules, oligonucleotides, and peptides. The company has established capabilities in targeted protein degradation (TPD) and emphasizes the importance of safety and efficacy evaluations through both in vitro and in vivo studies. By utilizing human data-driven transcriptomics and proteomics, Axcelead aims to identify and validate novel drug targets effectively. Their proprietary processes are designed to streamline the drug development timeline, reduce R&D costs, and facilitate the transition from candidate selection to IND filing, ultimately supporting their partners in delivering impactful therapies to patients worldwide.

Japan

Axcelead Drug Discovery Partners, Inc. will combine scientific excellence, world-class IP protection and state-of-the art GLP accredited facilities and capabilities to deliver integrated end-to-end early discovery.

Axcelead Drug Discovery Partners

Company Details